XML 48 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue
Total revenues during the years ended December 31, 2023, 2022, and 2021 were as follows (in thousands):
Year Ended December 31,
202320222021
Product sales, net:
IBSRELA$80,062 $15,600 $— 
XPHOZAH2,464 — — 
Total product sales, net82,526 15,600 — 
Licensing revenue35,809 35,031 5,013 
Product supply revenue6,121 1,527 907 
Collaborative development revenue— — 4,177 
Total revenues$124,456 $52,158 $10,097 
Schedule of Revenue from Customers as a Percentage of Total Product Revenue, Net
Revenue from the following Customers who contributed greater than 10% of our gross product revenue during the years ended December 31, 2023 and 2022 as a percentage of total gross product revenue was as follows:
Year Ended December 31,
20232022
BioRidge Pharma, LLC26.3 %— %
Cardinal Health21.6 %23.1 %
AmerisourceBergen Drug Corporation20.9 %26.8 %
McKesson Corporation17.2 %21.6 %
Revenues from Customers and collaboration partnerships accounting for more than 10% of total revenues during the years ended December 31, 2023, 2022 and 2021 were as follows:
Year Ended December 31,
202320222021
Kyowa Kirin29.0 %70.0 %100.0 %
Bioridge Phama24.0 %3.2 %— %
Cardinal19.8 %9.6 %— %
AmerisourceBergen Drug Corporation19.1 %11.1 %— %
McKesson15.7 %8.9 %— %
Schedule of Chargebacks, Discounts and Reserve Balances
The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
Discounts and ChargebacksRebates, Wholesaler and GPO FeesCopay and ReturnsTotal
Balance as of December 31, 2021$— $— $— $— 
Provisions825 2,721 2,502 6,048 
Credits/payments(683)(1,277)(1,244)(3,204)
Balance as of December 31, 2022142 1,444 1,258 2,844 
Provisions5,341 15,365 10,629 31,335 
Credits/payments(5,005)(12,575)(7,971)(25,551)
Balance as of December 31, 2023$478 $4,234 $3,916 $8,628